DealZone

Deals wrap: Where’s the bid?

August 2, 2010

A sign on the fence marks Genzyme's plant in the Boston, Massachsetts neighborhood of Allston March 24, 2010. REUTERS/Brian Snyder Chances are, every big pharmaceutical company is running the numbers and weighing the pros and cons of acquiring Genzyme, but the focus is on French drugmaker Sanofi-Aventis, which has yet to deliver a bid. Citi expects a Genzyme deal to be worth $19.7-20.5 billion. * View article * More coverage

The merger market is crawling at its slowest pace ever, with deals taking longer to close as players at every step move with extra caution amid fluctuating stock prices. * View article

WSJ takes a look at Goldman and its dealings with AIG. * View WSJ article

Post Your Comment

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/